EP4 Receptor Antagonist Compounds for Selective PGE2 Pathway Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting prostaglandin E2 (PGE2) synthesis, such as COX inhibitors, face challenges with significant side effects and an imbalanced risk-benefit ratio, necessitating a more specific approach to neutralize PGE2 biology without causing dose-limiting toxicities.
Innovation Solution
Development of novel compounds acting as selective prostaglandin E2 receptor 4 (EP4) antagonists to target and inhibit PGE2-mediated pathways in various diseases, including pharmaceutical compositions for treating conditions like abdominal aortic aneurysm, ankylosing spondylitis, Alzheimer's disease, atherosclerosis, cancer, diabetic nephropathy, endometriosis, inflammatory bowel disease, migraine, multiple sclerosis, osteoarthritis, and rheumatoid arthritis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If COX inhibitors are used to target PGE2 synthesis, then therapeutic effects are achieved, but significant side effects and dose-limiting toxicities occur
Solution Approach 1:
The invention segments the prostaglandin pathway by targeting specifically the EP4 receptor rather than inhibiting COX enzymes broadly. This selective approach divides the therapeutic action from the harmful effects, achieving PGE2 pathway modulation while avoiding the dose-limiting toxicities associated with non-specific COX inhibition.
Solution Approach 2:
The compound exhibits local quality by demonstrating selective affinity for the EP4 receptor subtype. This specificity ensures that therapeutic effects are concentrated at the target receptor while minimizing off-target effects, thereby reducing gastrointestinal, cardiovascular, and renal side effects associated with broader COX inhibition.
2Object-generated harmful factors
If broad COX inhibition is used to reduce PGE2 levels, then inflammatory responses are suppressed, but the risk-benefit ratio becomes imbalanced
Solution Approach 1:
The EP4 selective antagonist acts as an intermediary that specifically modulates the PGE2-EP4 signaling axis. This targeted intervention suppresses inflammatory responses mediated by PGE2-EP4 interactions without disrupting other prostaglandin pathways, thereby improving the risk-benefit ratio compared to broad COX inhibition.
3Object-affected harmful factors
If EP4 selective antagonists are developed, then side effects are reduced, but compound specificity and selectivity must be precisely achieved
Solution Approach 1:
The invention achieves EP4 selectivity by optimizing specific molecular parameters of the compound, including the substituted phenyl ring structure, heterocyclic moieties, and substituent patterns. These parameter adjustments fine-tune the compound's binding affinity and selectivity for EP4 while minimizing interactions with other receptors, thereby reducing side effects without compromising specificity.
Data Source
AI summary
The disclosures herein relate to novel compounds of formula (1):and salts thereof, wherein A, X, R1, R2, R3, R4, R10 and R11 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with EP4 receptors.